id stringlengths 7 16 | section stringlengths 0 887 |
|---|---|
108hr5299ih | Institution of the opposition proceeding
(a) Dismissal; institution
(1) Dismissal
The Director may dismiss an opposition request that the Director determines lacks substantial merit. The determination by the Director to dismiss an opposition request shall not be appealable. The dismissal of an opposition request sha... |
108hr5299ih | (2) Institution
If the Director receives 1 or more requests that meet the requirements of section 321 regarding the same patent by the Director and are not dismissed under paragraph (1), an opposition proceeding shall be promptly instituted pursuant to the request or requests, but not before a period of 9 months has e... |
108hr5299ih | (b) Parties
The parties to an opposition proceeding under this section shall be the patent owner and each opposer whose request meets the requirements of section 321 and has not been dismissed under subsection (a)(1). (c) Decision by panel
The Director shall assign the opposition proceeding to a panel of three admini... |
108hr5299ih | The decision shall be based upon the prosecution record that was the basis for the grant of the patent and the additional submissions by the parties to the opposition proceeding authorized under this chapter. The panel may, in appropriate cases, divide the opposition into separate proceedings if the opposition involves... |
108hr5299ih | The patent owner, in responding to an opposition request, shall file with the response, through affidavits or declarations, any additional factual evidence and expert opinions on which the patent owner relies in support of the response. 327. Amendment of claims
The patent owner is entitled to request amendment of any ... |
108hr5299ih | The panel may permit further requests for amendment of the claims only upon good cause shown by the patent owner. No amendment enlarging the scope of the claims of the patent shall be permitted in the opposition proceeding. 328. Discovery and sanctions
(a) Discovery
After an opposition proceeding is instituted under ... |
108hr5299ih | Such depositions shall be limited to cross-examination on matters relevant to the affidavit or declaration. No other discovery shall be permitted unless the panel determines that additional discovery is required in the interest of justice. The panel shall determine the schedule for the taking of discovery under this su... |
108hr5299ih | Supplemental submissions
The panel may permit one or more supplemental submissions to be made by any party to an opposition proceeding under this chapter, subject to the rights and limitations on discovery under section 328. 330. Hearing and briefs
Any party to an opposition proceeding under this chapter may request ... |
108hr5299ih | The panel may permit the partied to file briefs for the hearing, and shall permit cross-examination of all affiants and declarants in the hearing, either before the panel or by deposition taken under section 328. 331. Written decision
The panel shall issue a written decision on each issue of patentability with respect... |
108hr5299ih | The written decision shall become a final determination of the Office on the issues raised in the opposition unless a party to the opposition files a request for reconsideration and modification of the written decision within a period set by the panel, which shall not be less than two weeks from the date of the written... |
108hr5299ih | The determination of invalidity shall be based upon the broadest reasonable construction of the claim. (b) Evidence
The Federal Rules of Evidence shall apply to the opposition proceeding, except to the extent inconsistent with any provision of this chapter. 333. Reconsideration
If a request is filed for reconsiderati... |
108hr5299ih | Following any reconsideration, the panel shall either deny the request for modification of the written decision or grant the request and issue a modified written decision, which shall constitute the final determination of the Office on the issues raised in the opposition proceeding. 334. Appeal
A party dissatisfied wi... |
108hr5299ih | Certificate
When a decision of a panel in an opposition proceeding under the chapter has become final under section 331, 333, or 334, as the case may be, the Director shall issue and publish a certificate in accordance with the decision, canceling any claim of the patent determined to be unpatentable, and shall incorp... |
108hr5299ih | Estoppel
(a) Estoppel
(1) In general
Subject to paragraph (2), after a certificate has been issued under section 335 in accordance with the decision of the panel in an opposition proceeding, the determination with respect to an issue of invalidity raised by an opposer shall bar that opposer from raising, in any subs... |
108hr5299ih | (2) Exception
If an opposer in an opposition proceeding demonstrates, in a subsequent proceeding referred to in paragraph (1), that there is additional factual evidence that is material to an issue of fact actually decided in the opposition proceeding, and necessary to the final determination in the opposition proceed... |
108hr5299ih | (b) Expanded definition of opposer
For purposes of this section, the term opposer includes the person making the request under section 321, any real party in interest, and their successors in interest. (c) New party-in-Interest
If a proceeding arising by reason of additional factual evidence raised under subsection (... |
108hr5299ih | Duration of opposition
The determination of a panel in an opposition proceeding under this chapter, including any determinations pursuant to a request for reconsideration under section 133, shall be issued not later than 1 year after the date on which the opposition proceeding is instituted under section 325. Upon goo... |
108hr5299ih | Settlement
(a) In general
An opposition proceeding under this chapter shall be terminated with respect to any opposer upon the joint request of the opposer and the patent owner, unless the panel has issued a written decision under section 331 before the request for termination is filed. If the opposition is terminate... |
108hr5299ih | The written decision under section 331 shall thereafter be issued only with respect to issues of invalidity raised by opposers that remain in the opposition proceeding. (b) Agreements in writing
Any agreement or understanding between the patent owner and an opposer, including any collateral agreements referred to ther... |
108hr5299ih | The opposition with respect to the parties to the agreement or understanding shall not be terminated until a true copy of the agreement or understanding, including any such collateral agreements, has been filed in the Patent and Trademark Office. If any party filing such an agreement or understanding requests, the agre... |
108hr5299ih | (c) Discretionary actions reviewable
Any discretionary action of the Director under subsection (b) shall be reviewable under chapter 7 of title 5. 339. |
108hr5299ih | Intervening rights
Any proposed amended or new claim determined to be patentable and incorporated into a patent following an opposition proceeding under this chapter shall have the same effect as that specified in section 252 of this title for reissued patents on the right of any person who made, purchased, or used wi... |
108hr5299ih | Relationship with reexamination proceedings
(a) Estoppel
A patent for which an opposition proceeding has been instituted under this chapter may not thereafter be made the subject of a request under section 302 or 311 for reexamination, by the same opposer or on behalf of the same real party in interest, on the same c... |
108hr5299ih | (b) Staying of other proceedings
[If, after an opposition proceeding has been instituted under this chapter, a request for reexamination under section 302 or section 311 is made by or on behalf of a person other than the opposer or the same real party in interest, such reexamination shall be stayed during the pendency... |
108hr5299ih | Submissions by third parties
Section 131 of title 35, United States Code, is amended— (1) by striking The Director and inserting (a) In general.—The Director ; and (2) by adding at the end the following: (b) Third party submissions
Any party shall have the opportunity to submit for consideration and for inclusion in ... |
108hr5299ih | under section 102 or would have been obvious under section 103. The Director shall consider such submissions if the request— (1) is made in writing not later than— (A) 6 months after the date on which the patent application is published under section 122, or (B) before the date on which a notice of allowance is mailed ... |
108hr5299ih | (3) sets forth the teaching and applicability of each reference and the basis on which the submission is offered; and (4) includes a sworn declaration attesting to the relevance and accuracy of the submissions. Information submitted under this subsection shall be considered during the examination of the patent applicat... |
108hr5299ih | Effect of notices of infringement
A notice by a patent holder alleging infringement of the patent shall not be deemed sufficient to subject a recipient of the notice to liability for willful infringement of the patent unless the notice would cause the recipient to have standing in a proceeding pursuant to a motion for... |
108hr5299ih | Injunctions
Section 283 of title 35, United States Code, is amended— (1) by striking The several and inserting (a) In General.— The several ; and (2) by adding at the end the following: (b) Grounds for granting injunction
A court shall not grant an injunction under this section unless it finds that the patentee is li... |
108hr5299ih | In making or rejecting such a finding, the court shall not presume the existence of irreparable harm, but rather the court shall consider and weigh evidence, if any, tending to establish or negate any equitable factor relevant to a determination of the existence of irreparable harm, including, but not limited to, the e... |
108hr5299ih | (b) Applicability
Notwithstanding section 4608(a) of the Intellectual Property and Communications Reform Act of 1999, as enacted by section 1000(a)(9) of Public Law 106–113 (41 U.S.C. note), sections 311 through 318 of title 35, United States Code, as amended by this section, shall apply to any patent that issues from... |
108hr5299ih | Nonobviousness
Section 103 of title 35, United States Code, is amended by adding at the end the following: (d) (1) A business method invention shall be presumed obvious under this section if the only significant difference between the combined teachings of the prior art and the claimed invention is that the claimed in... |
108hr5299ih | (2) (A) An applicant or patentee may rebut the presumption under paragraph (1) upon a showing by a preponderance of the evidence that the invention is not obvious to persons of ordinary skill in all relevant arts. (B) Those areas of art which are relevant for purposes of subparagraph (A) include the field of the busine... |
108hr5299ih | Conforming amendments
(a) Definitions
Section 100(e) of title 35, United States Code, is amended by striking or inter partes reexamination under section 311 and inserting inter partes reexamination under section 311, or an opposition under section 321,. (b) Appeal to court of appeals
(1) Section 141 of title 35, Uni... |
108hr5299ih | (2) Section 143 of title 35, United States Code, is amended by inserting after the third sentence the following: In any opposition proceeding, the panel of administrative patent judges making the determination in the proceeding shall submit to the court in writing the grounds for the decision of the panel, addressing a... |
108hr4258ih | 1. Short title
This Act may be cited as the Rapid Pathogen Identification to Delivery of Cures Act. 2. Findings and policy
(a) Findings
The Congress finds as follows: (1) The possibility exists today that terrorists or others who intend harm to United States forces deployed abroad or to the homeland will use techniq... |
108hr4258ih | (2) This possibility will likely grow over time as such techniques develop, improve, and spread as an inevitable result of biotechnology innovation. (3) Natural processes can also lead to the emergence of previously unknown and harmful pathogens or render known pathogens resistant to existing diagnostic, therapeutic, o... |
108hr4258ih | These constraints reflect the long, costly research and development process, including the failure of most drug or vaccine candidates to demonstrate favorable characteristics in pre-clinical testing, as well as the expensive, time-consuming clinical trials required to prove the safety and effectiveness of new treatment... |
108hr4258ih | (6) There is no coordinated, focused research and development program or overall national strategy to achieve significant and dramatic reductions in the timeframe from the identification of a pathogen to the development and emergency approval for human use of reasonably safe and effective new biodefense medical counter... |
108hr4258ih | (7) Even utilizing existing technologies, there is no organized capability in the public or private sector to rapidly screen drug candidates for potential therapeutic activity against pathogens, develop and manufacture drug, biological, or medical device products, or test already approved treatments for efficacy agains... |
108hr4258ih | (9) Tremendous potential exists for benefits to health by concerted, targeted public-private investment to dramatically reduce the timeframe for the development of new countermeasures. The pharmaceutical and biotechnology industries are fundamentally innovative and are quick to integrate new technologies. Useful and im... |
108hr4258ih | (b) Policy
The Congress hereby declares it to be the national policy of the United States to promote technological advancements that will dramatically reduce the timeframe for the development of new medical countermeasures to treat or prevent disease caused by infectious disease agents or toxins that, through natural ... |
108hr4258ih | ( Public Law 107–296 ) is amended by inserting after section 304 the following section: 304A. |
108hr4258ih | Rapid biodefense countermeasures development national strategy
(a) National strategy for shortening the medical countermeasure development timeframe
Not later than 180 days after the date of the enactment of the Rapid Pathogen Identification to Delivery of Cures Act, the Secretaries of Homeland Security, Health and H... |
108hr4258ih | (b) Elements
The report under subsection (a) shall include the following: (1) The identification of the technical impediments to reductions in the timeframe from pathogen identification to priority countermeasure development and approval under emergency conditions. (2) The identification of the research, development, ... |
108hr4258ih | (4) The identification of facilities, programs and resources that can be utilized to address these research, development, and technology needs and clinical research needs among— (A) Federal agencies; (B) colleges and universities; (C) not-for-profit institutions; (D) industry, including information technology, software... |
108hr4258ih | including recommendations for the allocation and prioritization of Federal funds; (B) interagency management and coordination mechanisms; (C) the establishment of partnerships between private corporations and Federal agencies or Federally funded entities; (D) information and technology sharing and coordination mechanis... |
108hr4258ih | (6) The identification of potential liability concerns stemming from distribution of rapidly-developed priority countermeasures under emergency conditions and a proposal for regulatory or legislative approaches to eliminating these concerns. (7) A proposal for managing the transfer of new technologies and associated in... |
108hr4258ih | including— (A) initial identification and characterization of a pathogen or toxin, including the identification of any genetic or other manipulations; (B) priority countermeasures discovery; (C) pre-clinical testing and evaluation of priority countermeasures; (D) safety and efficacy animal testing, including the needs ... |
108hr4258ih | 2002 (67 Fed. Reg. 37988); (E) safety and efficacy human testing, including mechanisms for the conduct of clinical trials under emergency conditions; (F) research-scale and full production-scale manufacturing, including biologics manufacturing sciences; and (G) the approval of priority countermeasure under emergency co... |
108hr4258ih | and (4) the current state of national and international collaborative research networks and applications to facilitate and encourage the rapid and coordinated development and sharing of laboratory and clinical research planning and results. |
108hr4258ih | (d) Authority to contract
The Secretary of Homeland Security, after consultation with the Secretaries of Health and Human Services and Defense and the working group established under section 319F(a) of the Public Health Service Act, may contract with any one or more for-profit or non-profit firm or institution to cond... |
108hr4258ih | (e) Definitions
In this section: (1) The term emergency conditions refers to a declaration of emergency under section 564 of the Federal Food, Drug, and Cosmetic Act. (2) The term pathogen identification means the point in time in which a specific agent that can be reasonably assumed to be the cause of (or has the pot... |
108hr4258ih | (f) Authorization of appropriations
For the purpose of carrying out this section, there is authorized to be appropriated $10,000,000 for fiscal year 2005.. 304A. |
108hr4258ih | Rapid biodefense countermeasures development national strategy
(a) National strategy for shortening the medical countermeasure development timeframe
Not later than 180 days after the date of the enactment of the Rapid Pathogen Identification to Delivery of Cures Act, the Secretaries of Homeland Security, Health and H... |
108hr4258ih | (b) Elements
The report under subsection (a) shall include the following: (1) The identification of the technical impediments to reductions in the timeframe from pathogen identification to priority countermeasure development and approval under emergency conditions. (2) The identification of the research, development, ... |
108hr4258ih | (4) The identification of facilities, programs and resources that can be utilized to address these research, development, and technology needs and clinical research needs among— (A) Federal agencies; (B) colleges and universities; (C) not-for-profit institutions; (D) industry, including information technology, software... |
108hr4258ih | including recommendations for the allocation and prioritization of Federal funds; (B) interagency management and coordination mechanisms; (C) the establishment of partnerships between private corporations and Federal agencies or Federally funded entities; (D) information and technology sharing and coordination mechanis... |
108hr4258ih | (6) The identification of potential liability concerns stemming from distribution of rapidly-developed priority countermeasures under emergency conditions and a proposal for regulatory or legislative approaches to eliminating these concerns. (7) A proposal for managing the transfer of new technologies and associated in... |
108hr4258ih | including— (A) initial identification and characterization of a pathogen or toxin, including the identification of any genetic or other manipulations; (B) priority countermeasures discovery; (C) pre-clinical testing and evaluation of priority countermeasures; (D) safety and efficacy animal testing, including the needs ... |
108hr4258ih | 2002 (67 Fed. Reg. 37988); (E) safety and efficacy human testing, including mechanisms for the conduct of clinical trials under emergency conditions; (F) research-scale and full production-scale manufacturing, including biologics manufacturing sciences; and (G) the approval of priority countermeasure under emergency co... |
108hr4258ih | and (4) the current state of national and international collaborative research networks and applications to facilitate and encourage the rapid and coordinated development and sharing of laboratory and clinical research planning and results. |
108hr4258ih | (d) Authority to contract
The Secretary of Homeland Security, after consultation with the Secretaries of Health and Human Services and Defense and the working group established under section 319F(a) of the Public Health Service Act, may contract with any one or more for-profit or non-profit firm or institution to cond... |
108hr4258ih | (e) Definitions
In this section: (1) The term emergency conditions refers to a declaration of emergency under section 564 of the Federal Food, Drug, and Cosmetic Act. (2) The term pathogen identification means the point in time in which a specific agent that can be reasonably assumed to be the cause of (or has the pot... |
108hr4258ih | (f) Authorization of appropriations
For the purpose of carrying out this section, there is authorized to be appropriated $10,000,000 for fiscal year 2005. 4. Clinical research under emergency conditions
(a) In general
Not later than 180 days after the date of the enactment of this Act, the Secretary of Health and Hu... |
108hr4258ih | (b) Emergency fund
A fund is authorized to be established for use, at the discretion of the Secretary, solely for the support of clinical research as described in subsection (a). 5. Interagency working group
Section 319F(a) of the Public Health Service Act, as amended by Public Law 107–188 , is amended— (1) by insert... |
108hr4258ih | and (3) by inserting after subparagraph (C) the following subparagraph: (D) development of a national strategy to achieve dramatic reductions in the timeframe from the identification of a pathogen to the development and approval for human use under emergency conditions of priority countermeasures against a novel, unkno... |
108hr4258ih | by striking and after the semicolon; (2) by redesignating subparagraph (D) as subparagraph (E); and (3) by inserting after subparagraph (C) the following subparagraph: (D) the development of a capability to rapidly identify, develop, produce, and approve for human use under emergency conditions priority countermeasures... |
108hr4258ih | (b) Research and development at the Department of Defense
Section 1601(a) of the National Defense Authorization Act for Fiscal Year 2004 ( Public Law 108–136 ) is amended by adding at the end the following: The program shall also include research, development, and procurement to provide the Federal Government with the... |
108hr4258ih | (c) Research and development at the Department of Homeland Security
Title III of the Homeland Security Act of 2002, as amended by section 3 of this Act, is amended by inserting after section 304A the following section: 304B. |
108hr4258ih | Developing the capability for rapid biodefense countermeasure development
The Secretary, in collaboration with the Secretaries of Defense and Health and Human Services, shall carry out a program for research, development, and procurement to provide the Federal Government with the capability to rapidly identify, develo... |
108hr4258ih | Developing the capability for rapid biodefense countermeasure development
The Secretary, in collaboration with the Secretaries of Defense and Health and Human Services, shall carry out a program for research, development, and procurement to provide the Federal Government with the capability to rapidly identify, develo... |
108hr4946ih | 1. Short title
This Act may be cited as the United States Court of Federal Claims Termination Act of 2004. 2. Findings
Congress finds that— (1) a fair and efficient Federal judiciary is a bedrock of the Nation’s democracy; (2) at a time of rising deficits and shrinking budgets, it is imperative that Federal judiciary... |
108hr4946ih | 5 trials and spent less than 66 hours in a courtroom; (5) between calendar years 1997 and 2001, on average, Court of Federal Claims judges had 45 cases on their docket each year; (6) by contrast, during the same period, Federal district court judges had 478 cases on their dockets each year; (7) a comprehensive study by... |
108hr4946ih | (8) transferring the caseload of the Court of Federal Claims to the Federal district courts would add less than 1 case each year to each Federal district judgeship; (9) there is no evidence that Federal district courts are incapable of handling the caseload of the Court of Federal Claims; (10) it is estimated that the ... |
108hr4946ih | Termination of United States Court of Federal Claims
(a) Filing of claims
Notwithstanding any other provision of law, no claim may be filed in the United States Court of Federal Claims on or after the date of enactment of this Act. (b) Pending claims
Not later than 60 days after the date of enactment of this Act, th... |
108hr4946ih | Such transfers shall be completed during the 1-year period beginning on the date of enactment of this Act. Regulations under this subsection may provide for some claims to proceed in the United States Court of Federal Claims during that 1-year period. A congressional reference case for which a report is not transmitted... |
108hr4946ih | (d) Report
Not later than 60 days after the date of enactment of this Act, the Director of the Administrative Office of United States Courts shall submit a report to Congress containing recommendations for legislation to carry out this Act, including recommendations for conforming amendments to Federal law. |
108hr5418ih | 1. Contracts for use of excess capacity water in the Fryingpan-Arkansas Project
The Secretary of the Interior may enter into new and renewal contracts with the City of Aurora, Colorado, or an enterprise of the City, for a term not to exceed 50 years for the use of excess capacity in the Fryingpan-Arkansas Project for ... |
108hr5247ih | 1. Short title
This Act may be cited as the Constantine Menges Ukraine Democracy and Fair Elections Act of 2004. 2. Findings
Congress finds the following: (1) The United States supports the promotion of democracy, free, fair, and transparent elections, and respect for human rights and the rule of law in Ukraine consi... |
108hr5247ih | (3) Elections conducted by the Government of Ukraine during the past ten years have not satisfied the criteria established for free, fair, and transparent elections consistent with OSCE and European democratic standards. (4) Georgiy Gongadze, Igor Alexandrov, and other independent journalists in Ukraine who supported d... |
108hr5247ih | Kuchma and Prime Minister Viktor Yanukovych— (A) systematically harasses and represses independent media and independent trade unions and journalists; (B) actively suppresses freedom of speech and expression and encourages a virtual blackout on national television stations of the main democratic opposition candidate; (... |
108hr5247ih | (E) denies access of opposition candidates to rent government-owned auditoriums and public places for meetings with voters; and (F) denies postal service delivery of opposition campaign literature. |
108hr5247ih | (7) In spite of current and past statements by President Kuchma and Prime Minister Yanukovych that the up-coming presidential election will be free, fair, and transparent with an honest ballot count, the presidential election of October 1999, the national referendum of 2000, the parliamentary election of March 2002, an... |
108hr5247ih | (8) These elections failed to meet OSCE standards for democratic elections as formulated in the 1990 Copenhagen Document, and were marred by significant abusive and illegal misconduct that was publicly approved at the highest levels of the government, including— (A) the harassment, arrest, and false disqualification of... |
108hr5247ih | and the denial of the use of the postal system for sending opposition campaign mail to voters; (D) the seizure of equipment and property of independent nongovernmental organizations, radio stations, and press organizations and the harassment of their staff and management, causing several individuals to flee to foreign ... |
108hr5247ih | Constantine Menges, who died in July 2004, served as a senior official on the National Security Council under President Ronald Reagan and was a staunch anti-Communist, a friend of the peoples of Eastern European countries, and particularly supportive of Ukrainian independence. 3. Declaration of policy
Congress— (1) ex... |
108hr5247ih | (2) expresses it grave concern over the murders and disappearances of independent journalists in Ukraine like Georgiy Gongadze, Igor Alexandrov, and others; (3) calls upon the President Kuchma and Prime Minister Yanukovych to cease persecution of political opponents and independent journalists and to cease harassment o... |
108hr5247ih | expression, assembly, and association; and (5) calls upon the Government of Ukraine to resolve the continuing constitutional and political crisis by assuring— (A) a free, fair, and transparent presidential election in 2004; (B) meaningful access by the political opposition to state-controlled media, including access to... |
108hr5247ih | (F) modification of the electoral code in keeping with OSCE commitments; and (G) full freedom for international observers to monitor the election and ballot counting at local, regional, and national levels. 4. Sense of Congress regarding multilateral cooperation concerning Ukraine
It is the sense of Congress that the ... |
108hr5247ih | Sanctions against the Government of Ukraine
(a) Application and timing of sanctions
Until the President makes the determination that Ukraine meets all the requirements specified in subsection (b) and certifies such determination to the appropriate congressional committees, the President shall direct that the sanction... |
108hr5247ih | (b) Certification
A certification under this subsection is a certification transmitted to the appropriate congressional committees of a determination made by the president that the following has occurred with respect to Ukraine: (1) The implementation of free, fair, and transparent elections for president and Parliame... |
108hr5247ih | (3) The withdrawal and cessation of politically motivated legal charges against opposition figures and independent journalists. (c) Sanctions described
(1) Denial of entry into United States
The President shall direct the Secretary of Homeland Security to deny entry under section 212(f) of the Immigration and Nationa... |
108hr5247ih | (2) Seizure of assets in United States
The President shall direct the Office of Foreign Assets Control of the Department of the Treasury to identify and seize the personal assets or personal financial accounts in the United States obtained by improper or illicit means of any alien who— (A) is a senior government offic... |
108hr5247ih | or other similar financial assistance is provided on or after the date of the enactment of this Act by any agency of the United States, including by the Export-Import Bank of the United States and the Overseas Private Investment Corporation, to the Government of Ukraine (except with respect to the provision of humanita... |
108hr5247ih | (4) International financial institutions
The President shall direct the Secretary of the Treasury to instruct the United States executive director to each appropriate international financial institution in which the United States participates, to oppose and vote against the extension by each such institution of any lo... |
108hr5247ih | if the President determines— (A) that it is in the national security interest of the United States to do so; (B) that a new president is elected in Ukraine in November 2004 who— (i) has corrected the abuses and election irregularities outlined under section 2; and (ii) has pledged to conduct a free, fair, and transpare... |
108hr5247ih | such individual was not directly or indirectly involved in any of the abuses or election irregularities outlined under section 2. (2) Certification
If the President exercises the waiver under paragraph (1), the President shall submit to the appropriate congressional committees a report containing the reasons for such ... |
108hr5247ih | In the case of the second and all subsequent reports, each such report shall contain such information with respect to the preceding 12-month period. |
108hr5247ih | (b) Contents
The reports required by subsection (a) shall contain information regarding the following: (1) The personal assets and bank accounts of the current president, prime minister and other senior government officials of the Government of Ukraine that are located in the United States or other country, and, if su... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.